-
Mashup Score: 5SWOG Reporting Out for 2024: High Impact! | SWOG - 2 day(s) ago
Our leadership in science and innovation remains second to none, and in 2024 we had central roles in many of the National Cancer Institute’s most innovative clinical research initiatives. Obviously, I want you to read the report itself, so I won’t give away too much now. But here are a few tantalizing crumbs:
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1SWOG Latin America Initiative Levels Up | SWOG - 16 day(s) ago
Once again, we were lucky to have Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology (ASCO), attend and contribute. Her colleague Dr. Elizabeth Garrett-Mayer, vice president of ASCO’s Center for Research and Analytics, also joined in person and presented. My biggest takeaway from the conference? I continue to be astonished by the enthusiasm and engagement of our Latin America members. I could not be more impressed by, nor be happier to work with, them.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: SWOG Latin America Initiative Levels Up I continue to be astonished by the enthusiasm and engagement of our Latin America members. A recent trip to Peru also helped make clear to me how the value of that engagement has grown for SWOG. https://t.co/MbSpVjmAUr https://t.co/f869Xx7X85
-
-
Mashup Score: 5Pragmatica-Lung Closes, PROSPECT-Lung Opens | SWOG - 21 day(s) ago
Also known as CTIU2317-A082304-S2402 (I’ll stick with “PROSPECT-Lung”), the trial is co-led by the Alliance and SWOG, with the Alliance heading up administration. Co-chaired by Drs. Daniel Morgensztern (Alliance) and Raid Aljumaily (SWOG), it compares perioperative systemic therapy to adjuvant systemic therapy in patients with resectable early-stage non-small cell lung cancer (NSCLC).
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: Pragmatica-Lung Closes, PROSPECT-Lung Opens Pragmatica-Lung (S2302) has reached its accrual goal, enrolling 800 patients in 21 months. The moral? If you build it (properly), they will come. Amazing interest, amazing accrual. https://t.co/KxPUnBNWLG https://t.co/GWTS4HuWuj
-
-
Mashup Score: 4Modeling Adverse Event Risk Prediction: S2013 and S1501 Are Reopen to Enrollment! | SWOG - 30 day(s) ago
S2013, the I-CHECKIT trial, opens Cohort 2 to NCORP enrollment This observational study, aiming to develop and validate a risk prediction model for grade 3+ immune-related adverse events (irAEs) in patients on immune checkpoint inhibitor-based therapy, was temporarily closed earlier this year after reaching its Cohort 1 accrual target of 2,062 participants. The protocol has been revised, and the trial was reactivated on November 15th. Cohort 1 has closed, and a new cohort, Cohort 2, has been added.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: Modeling Adverse Event Risk Prediction: S2013 and S1501 Are Reopen to Enrollment! Two key trials by the @SWOG #NCORP Research Base have reopened after temporary closures. Both are prime examples of public-powered research. https://t.co/WIihLjFjgq https://t.co/7FiVeXBc5S
-
-
Mashup Score: 7
I’m also grateful to be able to announce that Dr. Jason Zell is the new co-chair of our prevention, screening, and surveillance committee, leading alongside continuing co-chair Dr. Banu Arun. He takes the spot vacated by Dr. Marian Neuhouser, who stepped down as committee co-chair at our fall group meeting.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: SWOG Is (I Am) Thankful for a New Committee Co-Chair, and Much More This Thanksgiving, I want to express my gratitude for our members' dedication to our patients and SWOG's mission -- commitment that's both humbling and inspiring. https://t.co/B0lsMaOS5q https://t.co/C1wJ07pPfh
-
-
Mashup Score: 0A Further Look at SWOG Radiopharmaceuticals | SWOG - 1 month(s) ago
I believe it may be unique in SWOG’s history in being a joint venture of two committees – in this case our radiation oncology and imaging committees (let me know if you’re aware of previous examples). That melding of these two modalities is ideal for theranostics – precision medicine that adapts radiopharmaceuticals for both diagnostics and treatment.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: A Further Look at @SWOG Radiopharmaceuticals Our radiation oncology and imaging committees have jointly launched a new subcommittee in theranostics – precision medicine that adapts radiopharmaceuticals for both diagnostics & treatment https://t.co/GSUZZNU7aG https://t.co/Qn0WvV8Rwc
-
-
Mashup Score: 1SWOG Latin America Initiative News: Summer 2024 | SWOG - 2 month(s) ago
Our newsletter will help keep you informed of SLAI accomplishments and of opportunities to activate trials in our member sites in Mexico, Peru, Chile, Colombia, and Uruguay. This issue highlights a new approach to international collaboration in SWOG, SLAI opportunities for cancer care delivery research, and new collaboration in lymphoma, and shines a spotlight on SWOG member site in Uruguay the Universidad de la República. You can read the issue here.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
And catch the latest update on the @SWOG #LatinAmericaInitiative here: https://t.co/FuuO5lXWF1 With special gratitude to @incanMX, which was the first institution outside the U.S. to appear on our list of top accruers to SWOG trials (in 2021)! https://t.co/7FWeloH4Oh
-
-
Mashup Score: 2Not Your Father’s Oldsmobile’s Dashboard | SWOG - 2 month(s) ago
I’m proud to report that many of these dashboards are now built and have already been deployed to the SWOG website! They’re designed to
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: Not Your Father’s Oldsmobile’s Dashboard We're building data dashboards to help @SWOG leaders & members better monitor progress, identify trends, and track performance. https://t.co/unALx9KGHv https://t.co/IRBIxq2rL5
-
-
Mashup Score: 1SWOG Latin America Initiative News: Summer 2024 | SWOG - 2 month(s) ago
Our newsletter will help keep you informed of SLAI accomplishments and of opportunities to activate trials in our member sites in Mexico, Peru, Chile, Colombia, and Uruguay. This issue highlights a new approach to international collaboration in SWOG, SLAI opportunities for cancer care delivery research, and new collaboration in lymphoma, and shines a spotlight on SWOG member site in Uruguay the Universidad de la República. You can read the issue here.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
And catch the latest update on the @SWOG #LatinAmericaInitiative here: https://t.co/FuuO5lXWF1 With special gratitude to @incanMX, which was the first institution outside the U.S. to appear on our list of top accruers to SWOG trials (in 2021)! https://t.co/7FWeloH4Oh
-
-
Mashup Score: 6Lung-MAP 3.0: The Next Generation | SWOG - 2 month(s) ago
Originally limited to patients with squamous cell lung cancer, in 2019 the trial expanded to include all histologies (Lung-MAP 2.0). Over its 10 years, it has activated 19 sub-studies, testing numerous new treatments, and has provided genomic testing for thousands of patients who otherwise would not have had it.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: Lung-MAP 3.0: The Next Generation The latest revision of the @LungMAP master protocol greatly expands the options for next-generation sequencing testing that can be used for matching patients to the trial's sub-studies in #NSCLC. https://t.co/OiUmxAF18t https://t.co/QShqn8lboE
-
Our @SWOGChair blog: SWOG Reporting Out for 2024: High Impact! We've just posted our SWOG Impact Report for 2024 https://t.co/9JWel7STJZ https://t.co/wslWxJrIez